Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer - ER+, HER2 -”

598 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 598 results

Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Not applicableStudy completedNCT05673850
What this trial is testing

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

Who this might be right for
Breast Neoplasms
Peking University 518
Early research (Phase 1)Looking for participantsNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 48
Testing effectiveness (Phase 2)Ended earlyNCT04504916
What this trial is testing

Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Who this might be right for
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLC+12 more
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 102
Not applicableLooking for participantsNCT06681064
What this trial is testing

Breast Cancer Evolution During Neoadjuvant Systemic Therapy

Who this might be right for
Breast CancerTriple Negative Breast CancerER+ Breast Cancer+1 more
Royal Marsden NHS Foundation Trust 500
Early research (Phase 1)WithdrawnNCT01320787
What this trial is testing

18-F-Fluoroacetate as PET Imaging Agent

Who this might be right for
Brain CancerBreast CancerProstate Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)Study completedNCT00629616
What this trial is testing

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 116
Testing effectiveness (Phase 2)Ended earlyNCT02202746
What this trial is testing

Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerMBC+5 more
Clovis Oncology, Inc. 178
Large-scale testing (Phase 3)Looking for participantsNCT05774951
What this trial is testing

Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Who this might be right for
Breast Cancer, Early Breast Cancer
AstraZeneca 4,300
Testing effectiveness (Phase 2)Study completedNCT03106077
What this trial is testing

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 96
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Testing effectiveness (Phase 2)Study completedNCT04352777
What this trial is testing

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerHormone Receptor Positive Tumor
Duke University 18
Testing effectiveness (Phase 2)Ended earlyNCT03070002
What this trial is testing

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Who this might be right for
Breast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor Positive+3 more
Northwestern University 1
Early research (Phase 1)Active Not RecruitingNCT03725436
What this trial is testing

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Load More Results